Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Daré Bioscience ( (DARE) ) has issued an announcement.
On June 9, 2025, Daré Bioscience, Inc. announced its intention to use a corporate presentation in meetings with securities market participants and others. The presentation will be accessible on the company’s website in the ‘Investors’ section. This move is part of Daré’s strategy to engage with stakeholders and provide transparency about its operations and future plans.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
Daré Bioscience’s overall stock score reflects significant financial challenges, including insolvency risk and negative equity. While strategic initiatives and cost management are positive, ongoing financial distress and regulatory challenges weigh heavily on the score. Technical indicators and valuation raise additional concerns, limiting the stock’s attractiveness.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Average Trading Volume: 19,692
Technical Sentiment Signal: Sell
Current Market Cap: $28.32M
Learn more about DARE stock on TipRanks’ Stock Analysis page.